Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism

Enclomiphene citrate : A treatment that maintains fertility in men with secondary hypogonadism / Joshua A. Earl, Edward D. Kim

  • Expert Review of Endocrinology & Metabolism 14 (2019) 3 (May), p. 157-165
  • PMID: 31063005
  • DOI: 10.1080/17446651.2019.1612239


Hypogonadism is an important issue among the male population. Treatments such as exogenous testosterone have become very popular. One of the adverse effects of testosterone is its suppression of fertility. This has lead to the use of alternative therapies such as selective estrogen receptor modulators (SERMs) that aim to correct hypogonadism without reducing fertility. Areas covered: The SERM, clomiphene citrate, which is approved by the FDA for the treatment of ovarian dysfunction, has been shown to have beneficial effects on male hypogonadism. Clomiphene citrate exists as a mixture of both the cis-isomer (zuclomiphene) and the trans-isomer (enclomiphene). The literature has suggested that most of the beneficial effects of clomiphene are due to the trans-isomer enclomiphene. Zuclomiphene contributes little to the intended outcomes. The purpose of this drug profile is to examine the available literature on the trans-isomer enclomiphene.

Expert opinion: Enclomiphene has been shown to increase testosterone levels while stimulating FSH and LH production. Initial studies demonstrated that enclomiphene maintains the androgenic benefit of clomiphene citrate without the undesirable effects attributable to zuclomiphene. This article reviews the difficulties associated with the FDA approval of a new molecular entity related to the treatment of hypogonadism.


7 May 2019
Earl, Joshua A.
Kim, Edward D.
United States of America
Other organisations
University of Tennessee Medical Center (UTMC)
Doping classes
S4. Hormone And Metabolic Modulators
Selective estrogen receptor modulators (SERMS)
Medical terms
Health effects
Document category
Date generated
4 January 2022
Date of last modification
8 January 2022
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period